文献速递真菌感染细菌感染、耐药与抗菌药物

艾沙康唑用于急性髓系白血病或骨髓增生异常综合征患者的一线抗真菌预防:一项开放标签、前瞻性2期研究

Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.
PubMed 文献 · Clin Infect Dis · 2021-01-01

这项开放标签、前瞻性2期研究评估了艾沙康唑在初诊急性髓系白血病或高危骨髓增生异常综合征患者接受缓解诱导化疗期间作为一线抗真菌预防的安全性和有效性。在包括末次给药后30天随访期内,确诊/临床诊断侵袭性真菌感染4例(6%),拟诊8例(12%);艾沙康唑谷浓度持续>1 µg/mL,个体内变异低,耐受性良好。

要点

  • 艾沙康唑预防期间确诊/临床诊断侵袭性真菌感染发生率为6%。
  • 艾沙康唑谷浓度持续>1 µg/mL,个体内变异低,不受化疗方案显著影响。
  • 耐受性良好,仅3例(5%)出现轻中度肝酶升高,无QTc延长。

核心结论

  • 在初诊AML/MDS接受缓解诱导化疗的患者中,艾沙康唑是安全有效的一线抗真菌预防选择。

主要发现

  • 包括末次给药后30天随访,确诊/临床诊断侵袭性真菌感染4例(6%),拟诊8例(12%)。
  • 艾沙康唑谷浓度持续>1 µg/mL,个体内变异低,不受化疗方案显著影响。
  • 仅3例(5%)出现轻中度肝酶升高,无QTc延长。

关键数值与推荐

  • 艾沙康唑按美国说明书剂量推荐给药,直至中性粒细胞恢复(ANC≥0.5×10^9/L)并达完全缓解、发生侵袭性真菌感染或最长12周。
  • 主要终点为艾沙康唑预防期间及末次给药后30天内确诊/临床诊断侵袭性真菌感染的发生率。

临床怎么用

  • 对于初诊AML/MDS接受缓解诱导化疗的患者,可考虑艾沙康唑作为一线抗真菌预防。
  • 艾沙康唑谷浓度持续>1 µg/mL且个体内变异低,支持其作为预防用药的暴露稳定性。
  • 艾沙康唑耐受性良好,肝酶轻度升高和QTc延长风险低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mold-active primary antifungal prophylaxis (PAP) is routinely recommended in neutropenic patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) undergoing remission-induction chemotherapy (RIC). Isavuconazole (ISAV) is an extended spectrum mold-active triazole and has superior tolerability and fewer significant drug-drug interactions compared with other triazoles. METHODS: In our investigator-initiated, phase 2 trial, treatment-naive adult patients with AML or MDS starting RIC received ISAV per the dosing recommendations in the US label until neutrophil recovery (absolute neutrophil count [ANC] ≥ 0.5 × 109/L) and attainment of complete remission, occurrence of invasive fungal infection (IFI), or for a maximum of 12 weeks. The primary endpoint was the incidence of proven/probable IFI during ISAV PAP and up to 30 days after the last dose. RESULTS: Sixty-five of 75 enrolled patients received ISAV PAP (median age, 67 years, median ANC at enrollment, 0.72 × 109/L). Thirty-two patients (49%) received oral targeted leukemia treatments (venetoclax, FTL3 inhibitors). Including the 30-day follow-up period, probable/proven and possible IFIs were encountered in 4 (6%) and 8 patients (12%), respectively. ISAV trough serum concentrations were consistently > 1 µg/mL, showed low intraindividual variation, and were not significantly influenced by chemotherapy regimen. Tolerability of ISAV was excellent, with only 3 cases (5%) of mild to moderate elevations of liver function tests and no QTc prolongations. CONCLUSIONS: ISAV is a safe and effective alternative for PAP in patients with newly diagnosed AML/MDS undergoing RIC in the era of recently approved or emerging small-molecule antileukemia therapies. CLINICAL TRIALS REGISTRATION: NCT03019939.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Bose P, McCue D, Wurster S, et al. Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study. Clin Infect Dis. 2021. PMID: 32236406. doi:10.1093/cid/ciaa358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。